A. Alper ÖZTÜRK, Gülsel YURTDAŞ KIRIMLIOĞLU

Preparation and in vitro characterization of lamivudine loaded nanoparticles prepared by acid and/or ester terminated PLGA for effective oral anti-retroviral therapy

The aim of this study was to formulate Lamivudine (LAM) loaded poly lactic-co-glycolic acid (PLGA)nanoparticle (NP) formulations by ‘double emulsion solvent evaporation’ method for oral administration. PLGA withsimilar molecular weight but two different chemical end-groups (acid or ester terminated), were used in this study toto compare the effects in the characterization of NPs. Particle size (PS), polydispersity index (PDI), zeta potential,entrapment efficiency (EE%), dissolution and release kinetic studies were carried out for the characterization of NPsand finally for determining the optimum formulation. The selected optimum formulation (B coded) was found to havea PS of 221.00.7 nm and a low PDI as 0.1040.014. Drug EE % of optimal NP formulation was found as 30.280%0.600.In vitro release of LAM loaded NPs were examined in phosphate buffer (pH 6.8). In vitro release studies of LAM-loadedNPs showed an extended release up to 144 hours, thus the demonstration of nanostructures was confirmed. Higuchiand Korsmeyer-Peppas kinetic model was found to fit best for LAM release from PLGA-NPs. The optimum formulationwas stable in the 24-hour gastrointestinal stability study and the NP structure was characterized by DSC, FT-IR and 1HNMRanalyzes. It could be concluded that LAM loaded NPs seem to be a promising extended release drug deliverysystem for oral administration in antiretroviral therapy. Lastly, in vitro characterization and release data demonstratedthe possibility of improved bioavailability of LAM by PLGA-NP formulation and the effect of polymers used in thisstudy on formulation characteristics were also elucidated

PDF

___

[1] Jena AK, Nayak AK, De A, Mitra D, Samantha A. Development of lamivudine containing multiple emulsions stabilized by gum odina. Fut J Pharm Sci. 2018; 4: 71-79. [CrossRef]
[2] Alebouyeh M, Amini H. Rapid determination of lamivudine in human plasma by high-performance liquid chromatography. J Chromatogr B. 2015; 975: 40-44. [CrossRef]
[3] Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999; 36(1): 41-66. [CrossRef]
[4] Sankara V, Nareshkumarb NP, Ajitkumarc GH, Penmetsad SD, Hariharane S. Comparative studies of lamivudinezidovudine nanoparticles for the selective uptake by macrophages. Curr Drug Deliv. 2012; 9: 506-514. [CrossRef]
[5] Öztürk AA, Çinar Nİ, Yenilmez E. Development of nano-sized ketoprofen lysine incorporated Eudragit® S100 nanomedicine by double emulsion solvent evaporation and in vitro characterization. J Pharm Pharmacogn Res. 2019; 7(1): 47–58.
[6] Öztürk AA, Martin Banderas L, Cayero Otero MD, Yenilmez E, Yazan Y. New approach to hypertension treatment: carvediol-loaded PLGA nanoparticles, preparation, in vitro characterization and gastrointestinal stability. Lat Am J Pharm. 2018; 37(9): 1730-1741.
[7] Makadia HK, Siegel SJ. Poly Lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polym. 2011; 3: 1377-1397. [CrossRef]
[8] Houchin ML. Topp EM. Chemical degradation of peptides and proteins in PLGA: A Review of Reactions and Mechanisms. J Pharm Sci. 2007; 97(7): 2395-2404. [CrossRef]
[9] Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-control parameters. Pro Polym Sci. 2011; 36(7): 887-913. [CrossRef]
[10] Wang B, Chen GQ, Mao ZW, Zhang YY, Yu DH, Gao CY. Preparation and cellular uptake of PLGA particles loaded with lamivudine. Chin. Sci. Bull. 2012; 57(31): 3985-3993.
[11] Bhattacharjee S. DLS and zeta potential – What they are and what they are not? J Control Release. 2016; 235: 337-351. [CrossRef]
[12] Kırımlıoğlu GY, Menceloğlu Y, Erol K, Yazan Y. In vitro/in vivo evaluation of gamma-aminobutyric acid-loaded N,N-dimethylacrylamide-based pegylated polymeric nanoparticles for brain delivery to treat epilepsy. J Microencapsul. 2016; 33(7): 625-635. [CrossRef]
[13] Öztürk AA, Yenilmez E, Yazan Y. Dexketoprofen trometamol-loaded Eudragit® RL 100 nanoparticle formulation, characterization and release kinetics. Acta Pharm Sci. 2018; 57(1): 69-84. [CrossRef]
[14] Huang W, Zhang C. Tuning the size of poly(lactic-co-glycolic acid) (PLGA) nanoparticles fabricated by nanoprecipitation. Biotechnol J. 2018; 13(1): 1-19. [CrossRef]
[15] Öztürk AA, Martin-Banderas L, Cayero Otero MD, Yenilmez E, Şenel B, Yazan Y. Dexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity. Trop J Pharm Res. 2019; 18(1): 1-11. [CrossRef]
[16] Danaei M, Dehghankhold M, Ataei S, Davarani FH, Javanmard R, Dokhanib A, Khorasani S, Mozafari MR. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmceutics. 2018; 10(57): 1-17. [CrossRef]
[17] Öztürk AA, Gündüz AB, Özışık O. Supervised machine learning algorithms for evaluation of solid lipid nanoparticles and particle size. Comb Chem High Throughput Screen. 2018; 21(9): 693-699. [CrossRef]
[18] Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Deliv. 2006; 3(4): 463–478. [CrossRef]
[19] Chigumira W, Maposa P, Gadaga LL, Dube A, Tagwireyi D, Maponga CC. Preparation and evaluation of pralidoxime-loaded PLGA nanoparticles as potential carriers of the drug across the blood brain barrier. J Nanomater. 2015; 692672: 1-5. [CrossRef]
[20] Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems—a review (Part 2). Trop J Pharma Res. 2013; 12(2): 265–273. [CrossRef]
[21] Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials. 2009; 30(3): 374-382. [CrossRef]
[22] de Jesus Gomes, Lunardi CN, Caetano FH, Lunardi LO, da Hora Machado AE. Phagocytosis of PLGA microparticles in rat peritoneal exudate cells: a time-dependent study. Microsc Microanal. 2006; 12(5): 399-405. [CrossRef]
[23] Kamala G, Vadrewu S, Valli N. Development and validation of RP-HPLC method for simultaneus estimation of lamivudine and zidovudine in bulk. Int J Curr Pharm Res. 2016; 8(1): 28-33.
[24] Öztürk AA, Yenilmez E, Yazan Y. Development and validation of high performance liquid chromatography (HPLC) modified method for dexketoprofen trometamol. Eur Int J Sci Tec. 2017; 6(5): 33-41
[25] Kırımlıoğlu GY, Yazan Y. Determination of gamma-aminobutyric acid by HPLC: Its application to polymeric nanoparticles and stability studies. Int J Develop Res. 2016; 6(6): 8277-8282.
[26] Chen G, Wen J. Poly(lactic-co-glycolic acid) based double emulsion nanoparticle as a carrier system to deliver glutathione sublingually. J Biomed. 2018; 3: 50-59. [CrossRef]
[27] Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. The AAPS J. 2010; 12: 263-271. [CrossRef]
[28] Basu T, Pal B, Singh S. Fabrication of core–shell PLGA/PLA–pNIPAM nanocomposites for improved entrapment and release kinetics of antihypertensive drugs. Particuology. 2018; 40: 169-176. [CrossRef]
[29] Peter Christoper GV, Vijaya Raghavan C, Siddharth K, Siva Selva Kumar M, Hari Prasad R. Formulation and optimization of coated PLGA - Zidovudine nanoparticles using factorial design and in vitro in vivo evaluations to determine brain targeting efficiency. Saudi Pharm J. 2013; 22(2): 133-40. [CrossRef]
[30] Öztürk AA, Yenilmez E, Şenel B, Arslan R, Yazan Y. Dexketoprofen trometamol-loaded Kollidon® SR and Eudragit® RS 100 polymeric nanoparticles: Formulation and in vitro-in vivo evaluation. Lat Am J Pharm. 2017; 36(11): 2153-2165.
[31] Singh AV, Nath LK. Evaluation of compatibility of tablet excipients and novel synthesized polymer with lamivudine. J Therm Anal Calorim. 2012; 108(1): 263-267. [CrossRef]
[32] Pang J, Luan Y, Li F, Cai X, Du J, Li Z. Ibuprofen-loaded poly(lactic-co-glycolic acid) films for controlled drug release. Int J Nanomedicine. 2011; 6: 659-65. [CrossRef]
[33] Öztürk AA, Güven UM, Yenı̇lmez E, Şenel B. Effects of different derivatives of eudragit polymer on entrapment efficiency, in vitro dissolution, release kinetics and cell viability results on extended release flurbiprofen loaded nanomedicines. Lat Am J Pharm. 2018; 37(10): 1981-1992.
[34] Kırımlıoğlu GY, Yazan Y, Erol K, Ünel ÇÇ. Gamma-aminobutyric acid loaded halloysite nanotubes and in vitro-in vivo evaluation for brain delivery. Int J Pharm. 2015; 495(2): 816-826. [CrossRef]
[35] Yenilmez E, Kırımlıoğlu GY, Şenel B, Başaran E. Preparation, characterization and in vitro evaluation of dirithromycin loaded Eudragit® RS 100 nanoparticles for topical application. Lat Am J Pharm. 2017; 36(11): 2203-2212.
[36] Pandey G, Yadav SK, Mishra B. Preparation and characterization of isoniazid and lamivudine co-loaded polymeric microspheres. Artif Cells Nanomed Biotechnol. 2016; 44(8): 1867-1877. [CrossRef]
[37] Singh G, Kaur T, Kaur R, Kaur A. Recent biomedical applications and patents on biodegradable polymer- PLGA. Int J Pharmacol Pharm Sci. 2014: 1(2): 30-42.
[38] Roy BN, Singh GP, Srivastava D, Aher UP, Patil SU. A stereoselective process for preparation of 1,3-oxathiolane nucleosides. 2013; Patent number: WO2013021290A1.